Open AccessActivity of Host Antimicrobials against Multidrug-Resistant Acinetobacter baumannii Acquiring Colistin Resistance through Loss of Lipopolysaccharide
Author(s) -
Meritxell GarcíaQuintanilla,
Marina R. Pulido,
Patricia Moreno-Martínez,
Reyes Martín-Peña,
Rafael López-Rojas,
Jerónimo Pachón,
Michael J. McConnell
Publication year - 2014
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02642-13
Subject(s) - acinetobacter baumannii , colistin , microbiology and biotechnology , antimicrobial , lipopolysaccharide , multiple drug resistance , antibiotics , lysozyme , biology , polymyxin , acinetobacter , antibiotic resistance , bacteria , immunology , pseudomonas aeruginosa , biochemistry , genetics
Acinetobacter baumannii can acquire resistance to the cationic peptide antibiotic colistin through complete loss of lipopolysaccharide (LPS) expression. The activities of the host cationic antimicrobials LL-37 and human lysozyme against multidrug-resistant clinical isolates ofA. baumannii that acquired colistin resistance through lipopolysaccharide loss were characterized. We demonstrate that LL-37 has activity against strains lacking lipopolysaccharide that is similar to that of their colistin-sensitive parent strains, whereas human lysozyme has increased activity against colistin-resistant strains lacking LPS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom